Gianfranco Gruttadauria

Dr. Gianfranco Gruttadauria

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
ATAndrea Tumminia
Andrea Tumminia
GPGiuseppe Papa
Giuseppe Papa
RCRossella Cannarella
Rossella Cannarella
FGFrancesco Galeano
Francesco Galeano
VOVittorio Oteri
Vittorio Oteri
Aldo E. CalogeroAldo E. Calogero
Aldo E. Calogero

17 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
CGCarmelo Gusmano
Carmelo Gusmano
Rossella CannarellaRossella Cannarella
Rossella Cannarella
CFConcetta Finocchiaro
Concetta Finocchiaro
GGGianfranco Gruttadauria
Gianfranco Gruttadauria
RRRosario Randazzo
Rosario Randazzo
GPGiuseppe Papa
Giuseppe Papa
Background and Aims: Automated insulin delivery (AID) systems are standard of care for type 1 diabetes mellitus (T1DM). Tubeless AID systems may improve treatment acceptance, but real-world European data in patients transitioning from multiple daily injections (MDI) or open-loop patch pump therapy are limited. This study evaluated real-world glycemic, safety, and quality-of-life (QoL) outcomes after transition to a tubeless automated closed-loop system (Omnipod 5®, OP5®). Research Design and Methods: In this prospective, multicenter observational study, adults with T1DM transitioned from MDI or open-loop continuous subcutaneous insulin infusion to OP5® and were followed for 180 days. Continuous glucose monitoring-derived metrics and validated patient-reported outcome measures were assessed. Subgroup analyses were performed by prior therapy. Results: Of the 94 enrolled participants, 88 completed the study. At 180 days, HbA1c decreased from 7.5% to 7.1% (p < 0.001), and time in range increased from 59.0% to 68.0% (p < 0.001) without increased hypoglycemia. The proportion achieving TIR70–180 ≥ 70% rose from 12.5% to 43.2%. Improvements were greater among prior MDI users. Treatment satisfaction and diabetes-related QoL improved significantly. The mean time in automated mode was 90.9%. Conclusions. Transition to tubeless AID significantly improved glycemic and psychosocial outcomes, supporting its effectiveness in routine clinical practice.